Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04056182
Recruitment Status : Completed
First Posted : August 14, 2019
Last Update Posted : February 2, 2021
Sponsor:
Collaborator:
US WorldMeds LLC
Information provided by (Responsible Party):
Frances R Levin, New York State Psychiatric Institute

Brief Summary:
This is an open-label pilot trial to evaluate the safety and tolerability of lofexidine in the management of opioid withdrawal symptoms while initiating outpatient treatment with naltrexone. The initiation procedure will be a flexible detoxification lasting 2 to 10 days concluding with the injection of XR-Naltrexone (Vivitrol). Vivitrol is a long-acting injection that contains enough medicine to last for one month blocking the effects of opioids.

Condition or disease Intervention/treatment Phase
Opioid-use Disorder Drug: Lofexidine 0.18 MG Phase 2

Detailed Description:
This is an open-label pilot trial to evaluate the safety and tolerability of lofexidine in the management of opioid withdrawal symptoms while initiating outpatient treatment with naltrexone. Lofexidine is a nonopioid prescription medicine used in adults to help with the symptoms of opioid withdrawal that may happen when a person stops taking an opioid suddenly. The initiation procedure will be a flexible detoxification lasting 2 to 10 days concluding with the injection of XR-Naltrexone (Vivitrol). Vivitrol is a long-acting injection that contains enough medicine to last for one month blocking the effects of opioids. Lofexidine will be fixed-flexible dosing started on day 1 with maximum dose being three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals. Lofexidine treatment will continue throughout the detoxification, up to 10 days, and will be discontinued with a gradual dose reduction over 2 to 4 days. Precipitated withdrawal symptoms are treated with lofexidine, clonazepam, and other comfort medications. After the induction patients will be seen at the clinic for 8 weeks. Twice weekly for the first month and weekly for weeks 5-8. A second Vivitrol injection will be provided at week 4.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: open label treatment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Lofexidine for Management of Opioid Withdrawal With XR-NTX Treatment
Actual Study Start Date : September 1, 2019
Actual Primary Completion Date : January 29, 2021
Actual Study Completion Date : January 29, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Lofexidine
Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
Drug: Lofexidine 0.18 MG
Lofexidine prescribed as three 0.18mg tablets taken orally 4 times daily at 4-to 6-hour intervals for 2-10 days for the management of opioid withdrawal symptoms prior to receiving Vivitrol.
Other Name: Lucemyra




Primary Outcome Measures :
  1. Successful Vivitrol induction [ Time Frame: up to 10 days of detoxification and induction ]
    number of participants inducted onto Vivitrol



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Individuals between the ages of 18-60
  • Meets DSM-5 criteria of current opioid use disorder present for at least six months, supported by a positive urine for opioids on day of consent
  • Seeking treatment for opioid use disorder
  • Capable of giving informed consent and complying with study procedures
  • History of opioid withdrawal

Exclusion Criteria:

  • Meets DSM-5 criteria for substance use disorder other than opioid as the primary diagnosis
  • Having a comorbid psychiatric diagnosis that might interfere with participation or make participation hazardous, such as an active psychotic disorder or current suicide risk
  • Methadone maintenance or long-acting agonist (buprenorphine) treatment -Buprenorphine maintenance treatment
  • Known history of allergy, intolerance, or hypersensitivity to candidate medication - - Pregnancy, lactation, or failure to use adequate contraceptive methods in female patients
  • Unstable medical conditions, which might make participation hazardous such as uncontrolled hypertension (blood pressure >150/100), acute hepatitis, uncontrolled diabetes, or elevated liver function tests (AST and ALT >3 times the upper limit of normal)
  • Legally mandated to substance use disorder treatment
  • Currently physiological dependence on alcohol or sedative-hypnotics that would require a medically supervised detoxification-other substance use diagnoses are not exclusionary
  • Painful medical condition that requires ongoing opioid analgesia or anticipated surgery necessitating opioid medications (Clinical interview; psychiatrist)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04056182


Locations
Layout table for location information
United States, New York
STARS/NYSPI-Columbia University
New York, New York, United States, 10019
Sponsors and Collaborators
Frances R Levin
US WorldMeds LLC
Investigators
Layout table for investigator information
Principal Investigator: FRANCES R (MD) R LEVIN, MD New York Psychiatric Institute
Layout table for additonal information
Responsible Party: Frances R Levin, Research Psychiatrist, New York State Psychiatric Institute
ClinicalTrials.gov Identifier: NCT04056182    
Other Study ID Numbers: 7812
First Posted: August 14, 2019    Key Record Dates
Last Update Posted: February 2, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: There is not a plan to make IPD available.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Frances R Levin, New York State Psychiatric Institute:
opioid use disorder
lofexidine
naltrexon-xr
Additional relevant MeSH terms:
Layout table for MeSH terms
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders
Lofexidine
Antihypertensive Agents
Narcotic Antagonists
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action